STOCK TITAN

[Form 4] GENELUX Corp Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

GENELUX Corp director Thomas John reported an open-market sale of 10,000 shares of common stock. The transaction occurred on March 2, 2026 at a weighted average price of $2.8957 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on June 4, 2025. Following this sale, he directly holds 482,784 shares.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Thomas John

(Last) (First) (Middle)
C/O GENELUX CORPORATION
2625 TOWNSGATE ROAD, SUITE 230

(Street)
WESTLAKE VILLAGE CA 91361

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
GENELUX Corp [ GNLX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/02/2026 S(1) 10,000 D $2.8957(2) 482,784 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2025.
2. The weighted average sale price for the transaction reported was $2.8957, and the range of prices were between $2.82 and $3.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
/s/ Thomas Zindrick ,J.D., Attorney-in-Fact 03/03/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did GENELUX Corp (GNLX) report for Thomas John?

GENELUX Corp reported that director Thomas John sold 10,000 shares of common stock. The sale was an open-market transaction executed under a Rule 10b5-1 trading plan, reflecting a pre-arranged disposition rather than an opportunistic trade based on short-term market movements.

At what price did Thomas John sell GENELUX (GNLX) shares in this Form 4?

Thomas John sold 10,000 GENELUX shares at a weighted average price of $2.8957. Footnotes state individual sale prices ranged between $2.82 and $3.01, and detailed information on shares sold at each price level is available upon request from the company, regulators, or shareholders.

How many GENELUX (GNLX) shares does Thomas John hold after this sale?

After selling 10,000 shares, Thomas John directly holds 482,784 GENELUX common shares. This remaining position is disclosed in the Form 4 as his total direct ownership following the reported open-market transaction executed under his Rule 10b5-1 trading plan.

Was the GENELUX (GNLX) insider sale made under a Rule 10b5-1 plan?

Yes, the sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Thomas John on June 4, 2025. Such plans allow insiders to pre-schedule trades, helping separate routine portfolio management from decisions based on non-public company information.

What does the Form 4 reveal about GENELUX (GNLX) insider trading activity overall?

The Form 4 reports one insider transaction: a net sale of 10,000 shares by director Thomas John. It shows no insider purchases or other acquisition transactions in this filing, indicating a single pre-planned disposition rather than multiple or mixed-direction trades during the reported period.
Genelux Corp

NASDAQ:GNLX

GNLX Rankings

GNLX Latest News

GNLX Latest SEC Filings

GNLX Stock Data

120.29M
39.83M
Biotechnology
Pharmaceutical Preparations
Link
United States
WESTLAKE VILLAGE